TULBURĂRILE HEMOSTAZEI LA PACIENȚII CU NSTEMI ȘI MARKERII DE DIAGNOSTIC
DOI:
https://doi.org/10.52692/1857-0011.2022.1-72.15Cuvinte cheie:
NSTEMI, dereglarea hemostazei, markeri procoagulanți, markerii ai sistemului antiocoagulant, markeri ai fibrinolizeiRezumat
Background. Hemostasis disorder is an important mechanism of cardiovascular disease, and its pathogenetic contribution to the evolution of NSTEMI is particularly notable in the context of the significance of the pathophysiological pattern caused by coronary microcirculation disorder. Highlighting imminent markers will facilitate the diagnosis and prognosis of NSTEMI. Object. Reporting literature summary data on markers with definite predictive value on proven hemostasis disorder in patients with NSTEMI. Results. The main markers of hemostasis disorder in NSTEMI and with predictive value on the diagnosis and evolution of post-infarction are:opposite the procoagulant system: elevation of microparticles derived from endotheliocytes and platelets expressing phosphotidylserine, activation of the complex of coagulation factors II, VII and X, formation of aggregates between platelets and leukocytes;opposite the anticoagulant system: increase in soluble thrombomodulin in combination with plasma decrease in antithrombin and C and S proteins;opposite the fibrinolytic system: elevation of the plasma levels of fibrin monomers and D-dimers of the plasminogen activator inhibitor in association with quantitative impairment of the plasminogen activator.
Referințe
Krychtiuk KA., Speidl WS., Giannitsis E., Gigante B., Gorog DA., Jaffe AS. et al. Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. Eur Hear Journal Acute Cardiovasc Care. 2021;10(3).
Ramberg C., Jamaly S., Latysheva N., Wilsgård L., Sovershaev T., Snir O. et al. A modified clot-based assay to measure negatively charged procoagulant phospholipids. Sci Rep. 2021;11(1).
Zarà M., Guidetti GF., Camera M., Canobbio I., Amadio P., Torti M. et al. Biology and role of extracellular vesicles (Evs) in the pathogenesis of thrombosis. Vol. 20, International Journal of Molecular Sciences. 2019.
Fotiou D., Sergentanis TN., Papageorgiou L., Stamatelopoulos K., Gavriatopoulou M., Kastritis E. et al. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer J. 2018;8(11).
Konkoth A., Saraswat R., Dubrou C., Sabatier F., Leroyer AS., Lacroix R. et al. Multifaceted role of extracellular vesicles in atherosclerosis. Vol. 319, Atherosclerosis. 2021.
Deng WY., Tang TT., Hou YF., Zeng Q., Wang YF., Fan WJ. et al. Extracellular vesicles in atherosclerosis. Vol. 495, Clinica Chimica Acta. 2019.
Wang L., Cao M., Bi Y., Ma R. Microparticles and blood cells induce procoagulant activity via phosphatidylserine exposure in NSTEMI patients following stent implantation. Int J Cardiology, 2016, 223. DOI:10.1016/j. ijcard.2016.07.260.
Hartopo AB., Puspitawati I., Gharini PP. et al. Platelet microparticle number is associated with the extent of myocardial damage in acute myocardial infarction. Arch Med Sci, 2016, 12(3): 529-537. DOI: 10.5114/ aoms.2016.59926.
Biassucci LM., DiVito L., DeMAria G. et al. Differences in Microparticle Release in Patients With Acute Coronary Syndrome and Stable Angina. Circulation Journal, 2012, 76: 2174-2182.
Pluta K., Porebska K., Urbanowicz T. et al. Platelet–Leucocyte Aggregates as Novel Biomarkers in Cardiovascular Diseases. Biology, 2022, 11, 224: DOI: 11, 224. https://doi.org/10.3390/biology11020224
Kosaki R., Minoura Y., Ogura K. et al. Thrmbomodulin can predict the incidence of second events in patients with acute coroanry syndrome: single-center retrospective study. Journal of Cardiology, 2018, 72(6): 494-500.
Chan S. Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol, 2006, 111(2): 280285. DOI: 10.1016/j.ijcard.2005.09.015.
Ismail D., Harun S., Alwi I., Tambunan KL. Anti-thrombin III, Protein C, and Protein S deficiency in acute coronary syndrome. Med J of Indonesia, 2002, 11(2):87. Doi:10.13181/mji.v11i2.54.
Tiong IY., Alkotob ML., Ghaffari S. Protein C deficiency manifesting as an acute myocardial infarction and ischaemic stroke. Heart. 2003; 89(2): E7. doi:10.1136/ heart.89.2.e7
Winter WE., Greene DN., Beal SG., Isom JA., Manning H., Wilkerson G., et al. Clotting factors: Clinical biochemistry and their roles as plasma enzymes. In: Advances in Clinical Chemistry. 2020.
Babes EE., Zaha DC., Tit DM., Nechifor AC., Bungau S., Andronie-Cioara FL. et al. Value of hematological and coagulation parameters as prognostic factors in acute coronary syndromes. Diagnostics. 2021;11(5).
Pieters M., Wolberg AS. Fibrinogen and fibrin: An illustrated review. Vol. 3, Research and Practice in Thrombosis and Haemostasis. 2019.
Memtsas VP., Arachchillage DRJ., Gorog DA. Role, laboratory assessment and clinical relevance of fibrin, factor XIII and endogenous fibrinolysis in arterial and venous thrombosis. Vol. 22, International Journal of Molecular Sciences. 2021.
Refaai MA., Riley P., Mardovina T., Bell PD. The Clinical Significance of Fibrin Monomers. Vol. 118, Thrombosis and Haemostasis. 2018.
Arthamin MZ., Parmadi L., Djatmiko DP., Lawanto ER. Analysis of soluble fibrin monomer as diagnostic marker for acute myocardial infarction and its correlation with cardiac troponin. I. Indones J Clin Pathol Med Lab. 2019;25(3).
Kim JY., Kim HK., Cho Jy et al. D-dimer/troponin ratio in the differential diagnosis of acute pulmonary embolism from non-ST elevation myocardial infarction. Korean J Inter Med, 2018, 34(6): 1263-1271. DOI: 10.3904/ kjim.2018.153
Gosai F., Mital P., Vadher A. et al. D-dimerr as a marker of severity of mycoardial infarction. J of Ind Coll of Cardiol, 2015, 5(4): 269-271. DOI: https://doi.org/10.1016/j.jicc.2015.07.006.
Biccirè F.G., Farcomeni A., Gaudio C. et al. D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: a systematic review and metanalysis. Thrombosis J. 2021, 19(102). DOI: https://doi.org/10.1186/s12959-021-00354-y.
Shantsila E., Montoro-Garcia S., Tapp LD. et al. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. Thromb Haemost, 2012, 108(1): 3240. DOI: 10.1160/TH12-01-0011.
Chandrasekar B. Endogenous fibrinolysis inhibitors in acute coronary syndrome. Am Heart J Plus, 2021, 10, 100058. DOI: https://doi.org/10.1016/j.ahjo.2021.100058.
Publicat
Număr
Secțiune
Licență
Copyright (c) 2022 Buletinul Academiei de Științe a Moldovei. Științe medicale
Această lucrare este licențiată în temeiul Creative Commons Attribution 4.0 International License.
